To the full analysis
Cooper Companies stock: growth
COOCooper Companies reported $4.09B in revenue for fiscal 2025, up 5.1% on the prior year, up 11% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
8.6%
per year from 2006 to 2025, per share 7.9%
Earnings (Annual rate)
9.6%
per year from 2006 to 2025, per share 1.2%
Free cash flow (Annual rate)
23.5%
per year from 2006 to 2025, per share 22.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.0% | 8.6% | 8.6% |
| Revenue per share | 10.6% | 8.2% | 7.9% |
| Earnings | 9.5% | 6.3% | 9.6% |
| Earnings per share | −17.3% | −7.7% | 1.2% |
| Free cash flow | 19.7% | 11.4% | 23.5% |
| Free cash flow per share | 19.3% | 11.0% | 22.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $858.96M | $66.23M | $7.85M |
| 2007 | $950.64M | −$11.19M | −$49.64M |
| 2008 | $1.06B | $65.48M | −$28.36M |
| 2009 | $1.08B | $100.55M | $129.22M |
| 2010 | $1.16B | $112.8M | $193.91M |
| 2011 | $1.33B | $175.43M | $232.62M |
| 2012 | $1.45B | $248.34M | $215.34M |
| 2013 | $1.59B | $296.15M | $237.8M |
| 2014 | $1.72B | $269.86M | $216.76M |
| 2015 | $1.8B | $203.52M | $147.95M |
| 2016 | $1.97B | $273.92M | $357M |
| 2017 | $2.14B | $372.9M | $466.4M |
| 2018 | $2.53B | $139.9M | $475.3M |
| 2019 | $2.65B | $466.7M | $421.1M |
| 2020 | $2.43B | $238.4M | $176.2M |
| 2021 | $2.92B | $2.94B | $524.2M |
| 2022 | $3.31B | $385.8M | $450.4M |
| 2023 | $3.59B | $294.2M | $215M |
| 2024 | $3.9B | $392.3M | $288.1M |
| 2025 | $4.09B | $374.9M | $433.7M |
Revenue by segment
How The Cooper Companies, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Coopervision67%
- Coopersurgical33%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Coopervision | $1.88B | $1.97B | $1.84B | $2.15B | $2.24B | $2.42B | $2.61B | $2.74B | 67% |
| Coopersurgical | $650.8M | $680.5M | $587.9M | $770.5M | $1.07B | $1.17B | $1.29B | $1.35B | 33% |
| Total revenue | $2.53B | $2.65B | $2.43B | $2.92B | $3.31B | $3.59B | $3.9B | $4.09B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Oct 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.